Effectiveness of Vitamin D in Primary Dysmenorrhoea

Vitamin D in the Treatment of Primary Dysmenorrhoea: A Prospective Randomised Controlled Trial

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02441530

Enrollment

143

Registered

2015-05-12

Start date

2012-11-30

Completion date

2013-10-31

Last updated

2015-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Dysmenorrhoea

Keywords

vitamin D

Brief summary

Vitamin D in the treatment of primary dysmenorrhoea. Design:Randomised controlled trial. Setting:In a university hospital. Population: 142 women aged 16-35 years. Methods: Patients were treated with 667 unit of vitamin D once a day, 200 unit of vitamin E once a day or 400 mg ibuprofen twice a day,2 days before the date of menstruation and continued through the first 3 days, for 2 months. Main outcome measures: Pain score. Results: Mean VAS of vitamin D group was 4,91, was 6,54 in the vitamin E group and was 4,02 in the ibuprofen group Conclusion:Vitamin D and vitamin E are effective in relieving the pain,but the effect of vitamin D are more prominent

Detailed description

An excessive uterine production of prostaglandins is the pathogenic trigger of dysmenorrhoea. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the currently accepted drugs for the management of this disorder. The capacity for synthesizing vitamin D and the presence of vitamin D receptor in human cycling endometrium have also been demonstrated. Because vitamin D reduces the synthesis of prostaglandins, a beneficial effect of vitamin D for the uterus is possible.Vitamin E inhibits the release of arachidonic acid and the conversion of arachidonic acid to prostaglandin via an action on the enzymes phospholipase A2 and cyclooxygenase.

Interventions

DIETARY_SUPPLEMENTVitamin D

DIETARY_SUPPLEMENTVitamin E

DRUGIbuprofen

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

16 Years to 35 Years

Healthy volunteers

Yes

Inclusion criteria

1. Women had regular menstrual cycles lasted 21 to 35 days, with menstruation lasting 3 to 7 days; 2. Women had to be in good health and taking no medications including calcium, magnesium, vitamin D and oral contraceptives. 3. Women had not a previous history of gynaecological disease, and a normal pelvic examination were eligible.

Exclusion criteria

1\) Previous and current use of intrauterine contraceptive devices within the 6 months to enrollment was not permitted

Design outcomes

Primary

Measure	Time frame
pain score ,make a mark on a 10-cm visual analog scale (VAS)	2 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026